



Market Announcement

3 October 2023

Noxopharm Limited (ASX: NOX) – Trading Halt

Description

The securities of Noxopharm Limited ('NOX') will be placed in trading halt at the request of NOX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 5 October 2023 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Senior Adviser, Listings Compliance



3 October 2023

ASX Limited
Listings Compliance, Melbourne
Rialto, South Tower
Level 50
525 Collins Street
Melbourne VIC 3000

Attention: Ms Melissa Kostopoulos (Senior Adviser, Listings Compliance (Melbourne))

By Email Only: tradinghaltsmelbourne@asx.com.au

Dear Ms Kostopoulos

TRADING HALT REQUEST

Noxopharm Limited [ASX:NOX] (**Company or Noxopharm**) hereby requests a trading halt in relation to the Company's ordinary shares quoted on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending an announcement by the Company to the market regarding the determination of the designation by FDA for pancreatic cancer drug candidate CRO-67 (**the Purpose**).

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

- The trading halt is necessary to assist Noxopharm in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated Purpose above.
- Noxopharm requests that the trading halt remain in place until the earlier of commencement of normal trading on Thursday, 5 October 2023, or when the announcement regarding the stated Purpose is released to the market.
- Noxopharm is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

For and on behalf of the Board of Noxopharm Limited.

Yours faithfully,

Dr Gisela Mautner
CEO and Managing Director

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US biotech company Nyrada Inc (ASX:NYR), which focuses on drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@atomicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.